1. Home
  2. TNXP vs CVGI Comparison

TNXP vs CVGI Comparison

Compare TNXP & CVGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$9.92

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Logo Commercial Vehicle Group Inc.

CVGI

Commercial Vehicle Group Inc.

HOLD

Current Price

$4.68

Market Cap

167.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
CVGI
Founded
2007
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
167.7M
IPO Year
2008
2004

Fundamental Metrics

Financial Performance
Metric
TNXP
CVGI
Price
$9.92
$4.68
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
544.8K
604.3K
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
316.18
EPS
N/A
0.04
Revenue
$13,107,000.00
$755,231,000.00
Revenue This Year
$558.11
$4.84
Revenue Next Year
$38.29
$5.36
P/E Ratio
N/A
$116.25
Revenue Growth
29.85
14.06
52 Week Low
$10.03
$1.29
52 Week High
$69.65
$5.88

Technical Indicators

Market Signals
Indicator
TNXP
CVGI
Relative Strength Index (RSI) 35.99 48.56
Support Level N/A $4.69
Resistance Level $13.18 $5.77
Average True Range (ATR) 0.93 0.28
MACD -0.22 0.00
Stochastic Oscillator 1.20 41.98

Price Performance

Historical Comparison
TNXP
CVGI

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About CVGI Commercial Vehicle Group Inc.

Commercial Vehicle Group Inc and its subsidiaries are a globalised provider of systems, assemblies, and components to international commercial vehicle markets and electric vehicle markets. It delivers real solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities it serves. The company has its manufacturing operations in the United States, Mexico, China, the United Kingdom, the Czech Republic, Ukraine, Morocco, Thailand, India, and Australia. Organisations' products are mainly sold in North America, Europe, and the Asia-Pacific region. It has three segments: Global Seating Segment, Global Electrical systmem, and Trim Systems and Components Segment, with the majority of revenue from Global Seating Segment.

Share on Social Networks: